Trial reportInternational journal of stroke : official journal of the International Stroke Society2013
Platelet-oriented inhibition in new TIA and minor ischemic stroke (POINT) trial: rationale and design.
Trial report in International journal of stroke : official journal of the International Stroke Society, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 55 papers, 6 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
55 citing papers in PubMed, 6 syntheses or guidelines pooled it.
- The Importance of Platelets Response during Antiplatelet Treatment after Ischemic Stroke-Between Benefit and Risk: A Systematic Review.International journal of molecular sciences · 2022Pooled it
- Multiple versus fewer antiplatelet agents for preventing early recurrence after ischaemic stroke or transient ischaemic attack.The Cochrane database of systematic reviews · 2020Pooled it
- Dual versus mono antiplatelet therapy for acute non- cardio embolic ischemic stroke or transient ischemic attack, an efficacy and safety analysis - updated meta-analysis.BMC neurology · 2020Pooled it
- Dual versus mono antiplatelet therapy for acute non-cardioembolic ischaemic stroke or transient ischaemic attack: a systematic review and meta-analysis.Stroke and vascular neurology · 2018Pooled it
- Efficacy and safety of short-term dual- versus mono-antiplatelet therapy in patients with ischemic stroke or TIA: a meta-analysis of 10 randomized controlled trials.Journal of neurology · 2016Pooled it
- Oral antiplatelet therapy for acute ischaemic stroke.The Cochrane database of systematic reviews · 2014Pooled it
- Observed Versus Predicted Stroke Risk After Transient Ischemic Attack: A Post Hoc Analysis of a Randomized Clinical Trial.Journal of the American Heart Association · 2026Trial
- Trial
- Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.The New England journal of medicine · 2018 · on this mapTrial
- Trial
- Treatment Effect of Clopidogrel Plus Aspirin Within 12 Hours of Acute Minor Stroke or Transient Ischemic Attack.Journal of the American Heart Association · 2016Trial
- Trial
- Effect of clopidogrel with aspirin on functional outcome in TIA or minor stroke: CHANCE substudy.Neurology · 2015Trial
- Article
- Clinical Efficacy and Safety of Dual Versus Single Antiplatelet Therapy in Lacunar Stroke.Basic and clinical neuroscience · 2025Article
- Capsular warning syndrome followed by right internal capsule infarction: A case report emphasising post-stroke rehabilitation.SAGE open medical case reports · 2025Article
- Rescue therapy of early neurological deterioration in lacunar stroke.BMC neurology · 2024Article
- Dementia after Ischemic Stroke, from Molecular Biomarkers to Therapeutic Options.International journal of molecular sciences · 2024Review
- Baseline Stroke Risk and Efficacy of Dual-Antiplatelet Therapy: A Post Hoc Analysis of the POINT Trial.Stroke · 2024Article
- Dual versus mono antiplatelet therapy in mild-to-moderate stroke during hospitalization.Annals of clinical and translational neurology · 2022Article
Corrections and comments
- Commented on by
Authors and funding
12 authors.
Funding
Abstract
backgroundIschemic stroke and other vascular outcomes occur in 10-20% of patients in the three-months following a transient ischemic attack or minor ischemic stroke, and many are disabling. The highest risk period for these outcomes is the early hours and days immediately following the ischemic event. Aspirin is the most common antithrombotic treatment used for these patients.
aimThe aim of POINT is to determine whether clopidogrel plus aspirin taken <12 h after transient ischemic attack or minor ischemic stroke symptom onset is more effective in preventing major ischemic vascular events at 90 days in the high-risk, and acceptably safe, compared with aspirin alone.
designPOINT is a prospective, randomized, double-blind, multicenter trial in patients with transient ischemic attack or minor ischemic stroke. Subjects are randomized to clopidogrel (600 mg loading dose followed by 75 mg/day) or matching placebo, and all will receive open-label aspirin 50-325 mg/day, with a dose of 162 mg daily for five-days followed by 81 mg daily strongly recommended. STUDY OUTCOMES: The primary efficacy outcome is the composite of new ischemic vascular events - ischemic stroke, myocardial infarction, or ischemic vascular death - by 90 days. The primary safety outcome is major hemorrhage, which includes symptomatic intracranial hemorrhage. DISCUSSION: Aspirin is the most common antithrombotic given to patients with a stroke or transient ischemic attack, as it reduces the risk of subsequent stroke. This trial expects to determine whether more aggressive antithrombotic therapy with clopidogrel plus aspirin, initiated acutely, is more effective than aspirin alone.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.